My father is 67 with Stage 4 Colon Cancer with liver metastases. RAS wild-type. What is the difference between targeted therapy vs standard chemo?
My father was recently diagnosed with sigmoid colon adenocarcinoma with multiple bilobar liver metastases. Next-generation molecular testing showed KRAS/NRAS Wild-Type and BRAF V600E negative. Doctor is recommending adding Cetuximab (Erbitux) to mFOLFOX6. How does targeted antibody differ from chemo?
Dr. Suresh H. Advani (Senior Consultant Medical Oncologist, Jaslok Hospital)
Here is how standard chemo and targeted therapy work synergistically:
1. Standard Chemotherapy (FOLFOX: 5-FU, Leucovorin, Oxaliplatin): Kills rapidly dividing cells by damaging DNA replication across the entire tumor.
2. Targeted Monoclonal Antibody (Cetuximab): In RAS wild-type tumors, the EGFR receptor on cancer cell surfaces drives relentless multiplication. Cetuximab locks onto this receptor, turning off the growth signal and flagging the cancer cells for destruction by immune natural killer (NK) cells.
3. The Goal in Liver Metastases: In Stage 4 colon cancer, combining Cetuximab with FOLFOX achieves deep and rapid tumor shrinkage (Response rate > 65%). If the liver metastases shrink sufficiently, an expert surgical team may perform curative-intent liver resection (Hepatectomy), turning an incurable Stage 4 into potential long-term disease-free survival.